Imaging study using a tracer to measure inflammation in joints and lungs
Part of Blood & lymphatic, Bones, joints & muscles, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests how a radioactive imaging medicine (a tracer called 68Ga-DOTA-Siglec-9) spreads in the body and how well it shows inflammation. It includes both healthy volunteers and people with active rheumatoid arthritis, vasculitis, or pulmonary sarcoidosis to see if the scan matches disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old
- If you join as a patient, you must have active rheumatoid arthritis, vasculitis, or pulmonary sarcoidosis
- If you are in the healthy-volunteer group, you must not have an infection or inflammation based on blood or other tests
- For rheumatoid arthritis: you must not have used disease-modifying anti-rheumatic drugs, biologic medicines, or corticosteroids in the last 2 weeks
- For vasculitis: you must not have used immunosuppressing medicines, and avoid high-dose glucocorticoids (at least 60 mg) in the last 2 weeks and avoid NSAIDs 1 day before the study
- For pulmonary sarcoidosis: you must avoid corticosteroids for 1 week and avoid NSAIDs 1 day before the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses special imaging to look at lymph vessels in people with rheumatoid arthritis (RA). The goal is to better understand changes in the lymph system in early versus long-standing RA and during certain treatments.
This study uses a PET scan with a special radioactive tracer (68Ga-DOTA-Siglec-9) to look at cancer in certain people. It may help doctors better see cancer-related activity and guide treatment planning for selected cancers.
This trial tests a new imaging scan (SPECT) that uses a special tracer (99mTc-TCR-FAPI) to see inflammation in the joints of people with rheumatoid arthritis. It aims to help doctors better understand and track disease activity.
This trial uses a special PET/CT scan with a tracer called 68Ga-FAPI-46 to see if it can better detect inflammation and scarring (fibrosis) in people with chronic diseases like scleroderma, pulmonary fibrosis, or rheumatoid arthritis. The goal is to improve diagnosis and monitoring.
This trial uses a special PET scan tracer to see where immune system signals are active in people with cancer. It may help doctors understand how your immune system is responding to the disease.
This study uses a special PET scan (68Ga-FAPI) to look at inflammation in the heart. It may help researchers understand heart failure and cardiac sarcoidosis better.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.